Anixa Biosciences Inc. Common Stock (ANIX)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for businesses that earn money and possess durable advantages. Anixa Biosciences is a development-stage oncology company with four employees, no meaningful revenue in the latest filed periods—fiscal 2025 revenue was n/a, while fiscal 2024 and fiscal 2023 each had $210,000. It continues to lose money: net loss was $10.9 million in fiscal 2025, $12.6 million in fiscal 2024, and $9.8 million in fiscal 2023; more recently, fiscal Q3 2026 lost $2.6 million. Trailing free cash flow was -$7.4 million, a FairStock-calculated FCF yield of -7.9%. The balance sheet has very low debt (D/E 0.01) and a FairStock Altman Z-score of 6.69, so solvency is not the immediate worry. But the FairStock Piotroski F-Score is 1/9, ROE is -73.17%, and ROCE is -41.92%, which tell me capital is being consumed, not compounded. I see no moat: there is no approved product and no revenue stream. At the 2026-10-13 close of $2.67, market cap is $92.8 million; FairStock calculations show P/B 6.36 and P/E -8.34, the latter meaningless against losses. The FairStock score is 42/100, and the Lynch category is none because the company lost money in each of the last four years. The 52-week range is $2.32-$5.46. Growth depends on clinical trial success and financing, not on present earnings. Graham would treat this as speculation unless the pipeline's value can be independently proven. I see no margin of safety in these numbers.

In plain English: Anixa Biosciences is a small company trying to develop cancer treatments and vaccines. It has almost no revenue and has lost money for years, including a net loss of $10.9 million in fiscal 2025. At $2.67 on 2026-10-13, the stock looks expensive compared with its current business numbers because profits and sales are not yet there.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-07-31) · fiscal Q2 2026 10-Q (period ended 2026-04-30) · fiscal Q1 2026 10-Q (period ended 2026-01-31) · fiscal Q3 2025 10-Q (period ended 2025-07-31) · FY2025 10-K (period ended 2025-10-31) · FY2024 10-K (period ended 2024-10-31) · FY2023 10-K (period ended 2023-10-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer